º»¹®/³»¿ë
spironolactone
aldosterone ±æÇ×Á¦
±âÀü : ¨ç DHTÀÇ ¼¼Æ÷³» ¼ö¿ëü¿¡ ´ëÇÑ °æÀïÀû ¾ïÁ¦
¨è P-450 °è¸¦ ÀúÇϽÃÄÑ Å×½ºÅ佺Å×·Ð »ýÇÕ¼º ¾ïÁ¦
¨é ¾Èµå·ÎÁ¨ÀÇ ÀÌÈ Áõ°¡
¨ê ÇǺΠ5¥á-reductase Ȱ¼ºµµ ¾ïÁ¦
100mg for 6 ms(70-80%¿¡¼ È¿°ú)
ºÎÀÛ¿ë : »ý¸®ºÒ¼ø, µÎµå·¯±â, À¯¹æÅë, µÎÇǸð¹ß¼Ò½Ç, ¿À½É, ÇÇ·Î,
, Ä®·ýÁõ°¡, ³²¼ºÅ¾ÆÀÇ ¿©¼ºÈ
(7) CPA
°·ÂÇÑ Ç׾ȵå·ÎÁ¨ Á¦Á¦
±âÀü : competition with testosterone and dihydrotestosterone
°£¿¡¼ ¾Èµå·ÎÁ¨ ´ë»çÃËÁø
¿ë·® : reverse sequential regimen
CPA (100mg/d #5-15) ;
EE2 (30-50¥ìg/d #5-26)
ºÎÀÛ¿ë : ÇÇ·Î. üÁßÁõ°¡. µÎÅë. ¼º¿å°¨Åð. ºÒ±ÔÄ¢ ÃâÇ÷. ¿À½É
(8) flutamide
ºñ½ºÅ×·ÎÀ̵å°è Ç׾ȵå·ÎÁ¨Á¦Á¦
ºÎÀÛ¿ë : ÇǺΰÇÁ¶, ¾È¸éÈ«Á¶, ½Ä¿åÁõ°¡, µÎÅë, ÇÇ·Î, ¿À½É, ¾îÁö·¯¿òÁõ, ¼º¿å°¨Åð, À¯¹æÅë
(9) cimetidine
È÷½ºÅ¸¹Î H2 ¼ö¿ëüÀÇ ±æÇ×Á¦
¾Èµå·ÎÁ¨ ¼ö¿ëü¿¡ °áÇÕÇϰųª ¸ð³¶ÀÇ DHT¿ÍÀÇ °áÇÕ ¾ïÁ¦
ÃÖ±Ùº¸°í¿¡ ÀÇÇϸé È¿¡¦(»ý·«)
(11) ³¼Ò¼³»ó ÀýÁ¦¼ú / laparoscopic ovarian electrocautery